SGLT2i treatment at the beginning of real time exposure in a HFrEF population

被引：0
|
作者：
Vintila, V. [1 ]
Ciocanel, A. [2 ]
Stamate, E. [2 ]
Vintila, A. M. [3 ]
Vinereanu, D. [1 ]
机构：
[1] Univ Med & Pharm Carol Davila, Univ & Emergency Hosp Bucharest, Cardiol Dept, Bucharest, Romania
[2] Univ Emergency Hosp Bucharest, Cardiol Dept, Bucharest, Romania
[3] Univ Med & Pharm Carol Davila, Internal Med Dept, Coltea Clin Hosp, Bucharest, Romania
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2024年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：251 / 251
页数：1
相关论文
共 50 条
  • [1] Real world experience of SGLT2i in HFrEF patients
    Saharudin, S.
    Yen, C. H.
    Tan, S. L.
    Kaukiah, N. F.
    Yong, V. S.
    Liew, H. B.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 393
  • [2] INDEPENDENT EFFECT OF SGLT2I ON DIASTOLIC FUNCTION IN HFREF POPULATION
    Stracqualursi, M.
    Nemola, G.
    Moscardelli, S.
    Santangelo, G.
    Buratti, S.
    Losito, M.
    Bursi, F.
    Guazzi, M.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2024, 26
  • [3] Real world registry of use of SGLT2i in patients with HFrEF followed in a non-tertiary hospital
    Martinez Mateo, V. Virgilio
    Cejudo Del Campo, L.
    Martin Barrios, E.
    Ibanez Leal, R.
    Serrano Blano, A.
    Gadella Fernandez, A.
    Paule, A. J.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 589 - 590
  • [4] Safety and Efficacy of the Combination of Sacubitril/Valsartan and SGLT2i in HFrEF Patients (SECSI Registry)
    Jimenez-Blanco Bravo, Marta
    Valle, Alfonso
    Gayan Ordas, Jara
    del Prado Diaz, Susana
    Cordero Pereda, David
    Morillas Climent, Herminio
    Bascompte Claret, Ramon
    Seller Moya, Julia
    Zamorano Gomez, Jose Luis
    Alonso Salinas, Gonzalo Luis
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2021, 78 (05) : e662 - e668
  • [5] Safety and efficacy of the combination of sacubitril/valsartan and SGLT2i in HFrEF patients (SECSI Registry)
    Marta Jimenez-Blanco Bravo, M.
    Del Prado Diaz, S.
    Cordero Pereda, D.
    Zamorano, J. L.
    Alonso Salinas, G.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 368 - 369
  • [6] REAL WORLD OUTCOMES OF SGLT2 INHIBITION IN A HFREF POPULATION
    Savage, Patrick
    McElhatton, Daniel
    Campbell, Michael
    Bamford, Jordan
    Reid, Rebecca
    Dixon, Lana
    HEART, 2022, 108 : A92 - A93
  • [7] Time to SGLT2i Initiation in Patients With Heart Failure
    Moon, Jungyeon
    Udell, Jacob A.
    Chong, Alice
    Fang, Jiming
    Austin, Peter
    Ko, Dennis T.
    Stukel, Therese
    Atzema, Clare
    Booth, Gillian
    Tu, Karen
    Naimark, David
    Jackevicius, Cynthia
    CIRCULATION, 2023, 148
  • [8] SHORT-TERM EFFECT OF SGLT2I ON ECHOCARDIOGRAPHIC PARAMETERS IN HFREF PATIENTS TREATED WITH ARNI
    Mazzetti, S.
    Cannistraci, R.
    Scifo, C.
    Acone, L.
    Alonge, S.
    Foti, M.
    Tarantini, R.
    Lattuada, G.
    Perseghin, G.
    Mortara, A.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24 (SUPPL C)
  • [9] Cardiorenal effects of SGLT2i in combination with ARNI for HFrEF: a systematic review and meta-analysis
    Cordovez, R. A. B.
    Rivera, K.
    Denila, R. A.
    Patricio, M.
    Permejo, C.
    EUROPEAN HEART JOURNAL, 2022, 43
  • [10] Perspective of SGLT2i in the Treatment of Abdominal Aortic Aneurysms
    Jin, Zhongtiao
    Deng, Hongping
    Xiong, Sizheng
    Gao, Ling
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2023, 81 (04) : 241 - 247
12345